pd-1_pd-l1在结直肠癌中的研究进展

《pd-1_pd-l1在结直肠癌中的研究进展》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153525中国图书分类号R735.3HebeiMedicalUniversity硕士学位论文专业学位PD-1/PD-L1在结直肠癌中的研究进展研究生：任中华导师：刘风玲教授专业：肿瘤学二级学院：第四医院2018年3月目录中文摘要··································································································1英文摘要······················································

2、······················································2英文缩写··········································································································3综述PD-1/PD-L1在结直肠癌中的研究进展···············································4致谢····················································

3、······························································25个人简历··········································································································26中文摘要PD-1/PD-L1在结直肠癌中的研究进展摘要程序性死亡受体-1(programmeddeath1，PD-1)与其配体(programmeddeath-ligand1，PD-L1)是目前免疫治疗中关注的焦点。PD-1与其配

4、体PD-L1结合导致肿瘤微环境中T细胞衰竭及免疫逃逸的发生，阻断PD-1与PD-L1结合是有效的治疗靶点。针对阻断PD-1/PD-L1通路的单克隆抗体已通过美国FDA的审批应用于临床，并已证实在恶性黑色素瘤、肺癌、膀胱癌、胃癌、霍奇金淋巴瘤、乳腺癌等多种恶性肿瘤的治疗中取得了显著效果，目前该疗法在结直肠癌（colorectalcancer，CRC）研究中也显示出了良好的疗效。本文对当前PD-1/PD-L1的分子结构、肿瘤免疫中的生物学功能、PD-1/PD-L1免疫组化检测以及与结直肠癌临床病理分子特点及预后关系、微环境中特点关系、PD-1/PD-L1抑制剂治疗与耐药方面的研究

5、进展作一综述。关键词：结直肠癌，免疫治疗，程序性死亡受体-1，程序性死亡配体-1，研究进展1英文摘要ResearchadvancesofPD-1/PD-L1incolorectalcancerABSTRACTTheprogrammeddeath1(PD-1)anditsligand1(PD-L1)arethefocusofcurrentimmunotherapy.ThecombinationofPD-1anditsligandPD-L1leadstotheoccurrenceofTcellfailureandimmuneescapeintumormicroenvironmen

6、t.BlockingPD-1bindingtoPD-L1isaneffectivetherapeutictarget.MonoclonalantibodiesagainstPD-1/PD-L1pathwayshavebeenapprovedbytheUSAFDAforclinicaltrialsandhavebeenidentifiedinmalignantmelanoma,lungcancer,bladdercancer,gastriccancer,Hodgkin'slymphoma,breastcancerhavingachievedremarkableresults.T

7、hecurrenttreatmentincolorectalcanceralsoshowedagoodeffect.Atpresent,theresearchprogressofthemolecularstructureandexpressionofPD-1/PD-L1,thebiologicalfunctionoftumor,PD-1/PD-L1immunohistochemistrytesting,theclinicalfeaturesandprognosisofcolorectalcancer,t